Fight CRC Clinical Trial Finder

添加审判日期
View:
NCT ID Title 阶段 Date Added 地点 Prior IO Allowed CRC-directed Status 药物 标签
NCT ID
NCT04362839
TitleRegorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer 阶段
第 1 阶段
Date Added
2020-04-27
地点
California, United States
Prior IO Allowed
没有
CRC-directed
Status
活跃,非招募
药物
Ipilimumab, Nivolumab, Regorafenib, Opdivo, Stivarga, Yervoy
标签
MSS/ MMRp
NCT ID
NCT04110093
Title瑞戈非尼加 PD-1 抑制剂治疗结直肠癌患者 阶段
第 1 阶段/第 2 阶段
Date Added
2019-10-01
地点
中国
Prior IO Allowed
CRC-directed
Status
招聘
药物
瑞戈非尼和 PD-1 抑制剂
标签
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT06006923
TitleRegorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer 阶段
第二阶段
Date Added
2023-08-23
地点
California, United States
Florida, United States
Illinois, United States
Pennsylvania, United States
Washington, United States
Prior IO Allowed
没有
CRC-directed
Status
招聘
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga
标签
MSI-H/ MMRd
NCT ID
NCT06456515
TitleRegorafenib and Sintilimab in Combination With Electroacupuncture in MSS CRC 阶段
不适用
Date Added
2024-06-13
地点
中国
Prior IO Allowed
CRC-directed
Status
招聘
药物
标签
MSS/ MMRp
NCT ID
NCT03657641
TitleRegorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer 阶段
第 1 阶段
Date Added
2018-09-05
地点
California, United States
Florida, United States
Prior IO Allowed
CRC-directed
Status
活跃,非招募
药物
Pembrolizumab, Regorafenib, Keytruda, Stivarga
标签
MSS/ MMRp
NCT ID
NCT04626635
TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors 阶段
Phase 1, Phase 2
Date Added
2020-11-12
地点
California, United States
Florida, United States
Illinois, United States
Iowa, United States
Massachusetts, United States
Michigan, United States
New Jersey, United States
New York, United States
Ohio, United States
Pennsylvania, United States
Tennessee, United States
Texas, United States
Wisconsin, United States
法国
以色列
荷兰
波兰
西班牙
Turkey
Prior IO Allowed
CRC-directed
没有
Status
招聘
药物
cemiplimab, REGN7075
标签
MSS/ MMRp
NCT ID
NCT03388632
Title重组白细胞介素-15 与检查点抑制剂 Nivolumab 和 Ipilimumab 联合治疗难治性癌症患者 阶段
第 1 阶段
Date Added
2018-01-03
地点
Maryland, United States
Prior IO Allowed
CRC-directed
没有
Status
招聘
药物
Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy
标签
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05785325
TitleRC48-ADC 联合贝伐单抗治疗 HER2 阳性晚期结直肠癌 阶段
第二阶段
Date Added
2023-03-27
地点
中国
Prior IO Allowed
CRC-directed
Status
招聘
药物
RC48-ADC 加贝伐单抗
标签
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05292417
TitleRadiotherapy in Combination With Sintilimab,GM-CSF and Fruquintinib in Patients With MSS mCRC 阶段
第二阶段
Date Added
2022-03-23
地点
中国
Prior IO Allowed
没有
CRC-directed
Status
招聘
药物
Fruquintinib, GM-CSF, Sintilimab
标签
MSS/ MMRp
NCT ID
NCT04050709
TitleQUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers 阶段
第 1 阶段
Date Added
2019-08-08
地点
California, United States
Prior IO Allowed
没有
CRC-directed
没有
Status
活跃,非招募
药物
PD-L1 t-haNK
标签
MSS/ MMRp